Cover Image
QR Code

Sharing real-world experiences to optimize the management of olaparib toxicities: a practical guidance from an Italian expert panel.

Olaparib is the first poly(ADP-ribose) polymerase inhibitor approved as maintenance therapy of recurrent ovarian cancer (OC) patients with a BRCA mutation. To achieve the maximum clinical benefit, adherence to olaparib must be persistent. However, in clinical practice, this is challenged by the freq...

Full description

Published in:Supportive Care in Cancer Vol. 28; no. 5; pp. 2435 - 2443
Main Authors: Lorusso, Domenica, Bologna, Alessandra, Cecere, Sabrina Chiara, De Matteis, Elisabetta, Scandurra, Giusy, Zamagni, Claudio, Arcangeli, Valentina, Artioli, Fabrizio, Bella, Mariangela, Blanco, Giusi, Cardalesi, Cinzia, Casartelli, Clelia, De Vivo, Rocco, Di Napoli, Marilena, Gisone, Emanuele Baldo, Lauria, Rossella, Lissoni, Alberto Andrea, Loizzi, Vera, Maccaroni, Elena, Mangili, Giorgia
Format: Journal Article
Published: Springer Nature May2020
Online Access:View this record in EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=142355181&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 142355181
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        09414355
        O1J
      jtl: Supportive Care in Cancer
      issn: 09414355
      maglogo: N
    pubinfo:
      dt: May2020
      vid: 28
      iid: 5
      pid: 237
      pub: Springer Nature
      place: New York, New York
    artinfo:
      ui:
        142355181
        142355181
        NLM32048043
        10.1007/s00520-020-05320-4
        NLM32048043
        142355181
      ppf: 2435
      ppct: 8
      formats:
        fmt:
          – @attributes:
              type: T
          – @attributes:
              type: P
      tig:
        atl: Sharing real-world experiences to optimize the management of olaparib toxicities: a practical guidance from an Italian expert panel.
      aug:
        au:
          Lorusso, Domenica
          Bologna, Alessandra
          Cecere, Sabrina Chiara
          De Matteis, Elisabetta
          Scandurra, Giusy
          Zamagni, Claudio
          Arcangeli, Valentina
          Artioli, Fabrizio
          Bella, Mariangela
          Blanco, Giusi
          Cardalesi, Cinzia
          Casartelli, Clelia
          De Vivo, Rocco
          Di Napoli, Marilena
          Gisone, Emanuele Baldo
          Lauria, Rossella
          Lissoni, Alberto Andrea
          Loizzi, Vera
          Maccaroni, Elena
          Mangili, Giorgia
        affil: Division of Gynecologic Oncology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Largo Agostino Gemelli 8, 00168, Rome, Italy
      sug:
        subj:
          Antineoplastic Agents Adverse Effects
          Ovarian Neoplasms Drug Therapy
          Heterocyclic Compounds Adverse Effects
          Antineoplastic Agents Therapeutic Use
          Italy
          Heterocyclic Compounds Therapeutic Use
          Proteins
          Mutation
          Neoplasm Recurrence, Local Drug Therapy
          Fatigue Chemically Induced
          Female
          Vomiting Chemically Induced
          Anemia Chemically Induced
          Nausea Therapy
          Nausea Chemically Induced
          Ovarian Neoplasms
          Scales
          Female
      ab: Olaparib is the first poly(ADP-ribose) polymerase inhibitor approved as maintenance therapy of recurrent ovarian cancer (OC) patients with a BRCA mutation. To achieve the maximum clinical benefit, adherence to olaparib must be persistent. However, in clinical practice, this is challenged by the frequent suboptimal management of toxicities. In view of the expanding use of olaparib also in Italy, physicians must learn how to adequately and promptly manage drug toxicities not to unnecessarily interrupt or reduce the dose. The experts agreed that nausea,vomiting, anemia, and fatigue are the most frequent events experienced by OC patients on olaparib, and that these toxicities usually develop early during treatment, are mainly of grade 1-2 and transient and can be managed with simple non-pharmacological interventions. By sharing their real-world experiences, the panel prepared, for each toxicity, an algorithm organized by grade and besides the procedures indicated in the local label, included supportive care interventions based also on nutritional and lifestyle modifications and psycho-oncology consultation. Moreover, in view of the tablet entry into the Italian market, the full and reduced dosages of capsules and tablets were compared. This practical guidance is intended to be a tool to support especially less-experienced physicians in the management of these complex patients, with the aim to help preventing the worsening of patients' conditions and the unnecessary interruption/reduction of olaparib dosage, which may jeopardize treatment efficacy.
      pubtype: Academic Journal
      doctype: Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N